We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Differentiated Human Stem Cells Repair Bone Damage in Mouse Model

By LabMedica International staff writers
Posted on 05 Jun 2012
Human-induced pluripotent stem cells (hiPSCs) derived from skin have been cultured in a novel cell and serum-free growth system and then differentiated into mature bone cells that were used to repair damage to bones in a mouse model.

In 2010, investigators at the University of Michigan (Ann Arbor, USA) described a novel growth system for the culture of hiPSCs. More...
The key to the technique was a synthetic polymer coating, poly[2-(methacryloyloxy)ethyl dimethyl-(3-sulfopropyl)ammonium hydroxide] (PMEDSAH), used in conjunction with a cell and serum-free culture medium.

In the current study, which was published in the May 15, 2012, online edition of the journal Stem Cells, the investigators tested the hypothesis that iPSCs could be maintained in an undifferentiated state in this culture system and subsequently be differentiated into mesenchymal stem cells (iPS-MSCs).

They showed that hiPSCs could be cultured on PMEDSAH and then differentiated into functional MSCs, as confirmed by expression of characteristic MSC biomarkers. To demonstrate the potential of iPS-MSCs to regenerate bone in vivo, the newly derived cells were induced to osteoblast differentiation for four days and then transplanted into immunocompromised mice for eight weeks in order to repair five-millimeter holes in the skulls of the mice. MicroCT (an X-ray computed tomography scanner for small animals) and histologic analyses demonstrated de novo bone formation in the holes in the skulls of animals treated with iPS-MSCs but not for the control group.

By the end of the eight weeks, the mice that had received human-derived bone cells had 4.2 times as much new bone as the controls, as well as the beginnings of marrow cavities. Positive staining for human nuclear antigen and human mitochondria monoclonal antibodies confirmed the participation of the transplanted hiPS-MSCs in the regenerated bone.

"We turn back the clock, in a way," said senior author Dr. Paul Krebsbach, professor of dentistry and biomedical engineering at the University of Michigan. "We are taking a specialized adult cell and genetically reprogramming it, so it behaves like a more primitive cell. The concept is not specific to bone. If we truly develop ways to grow these cells without mouse or animal products, eventually other scientists around the world could generate their tissue of interest."

Related Links:
University of Michigan



New
Gold Member
Hematology Analyzer
Medonic M32B
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.